Evidence map›Paper›PMID 30112119›Full record

ArticleOncotarget2018

Correction: Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes.

M Teresa Cedena, Inmaculada Rapado, Alejandro Santos-Lozano, Rosa Ayala, Esther Onecha, María Abaigar, Esperanza Such, Fernando Ramos, José Cervera, María Díez-Campelo and 4 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

M Teresa Cedena *Hematology Department, Hospital Universitario 12 Octubre, CNIO, Universidad Complutense, Madrid, Spain.
Inmaculada Rapado *Hematology Department, Hospital Universitario 12 Octubre, CNIO, Universidad Complutense, Madrid, Spain.
Alejandro Santos-LozanoResearch Institute of Hospital 12 de Octubre ('i+12'), Madrid, Spain.
Rosa AyalaHematology Department, Hospital Universitario 12 Octubre, CNIO, Universidad Complutense, Madrid, Spain.
Esther OnechaHematology Department, Hospital Universitario 12 Octubre, CNIO, Universidad Complutense, Madrid, Spain.
María AbaigarIBSAL, Cancer Research Center (USAL-CSIC), Salamanca, Spain.
Esperanza SuchHematology Department, Hospital Universitario La Fe, Valencia, Spain.
Fernando RamosHematology Department, Hospital Universitario de León, and IBIOMED, Universidad León, León, Spain.
José CerveraHematology Department, Hospital Universitario La Fe, Valencia, Spain.
María Díez-CampeloIBSAL, Cancer Research Center (USAL-CSIC), Salamanca, Spain.
Guillermo SanzHematology Department, Hospital Universitario La Fe, Valencia, Spain.
Jesús Hernández RivasIBSAL, Cancer Research Center (USAL-CSIC), Salamanca, Spain.
Alejandro LucíaResearch Institute of Hospital 12 de Octubre ('i+12'), Madrid, Spain.
Joaquin Martínez-LópezHematology Department, Hospital Universitario 12 Octubre, CNIO, Universidad Complutense, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.18632/oncotarget.22157.].

Identifiers

PMID30112119
PMCPMC6089387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.